Eckardt, Franziska https://orcid.org/0000-0001-5883-2529
Hafner, Michael
Lorger, Anna
Liesenhoff, Caspar
Schiefelbein, Johannes
Herold, Tina Rieke
Luft, Nikolaus
Klaas, Julian Elias
Schworm, Benedikt
Priglinger, Siegfried Georg
Siedlecki, Jakob
Funding for this research was provided by:
Klinikum der Universität München
Article History
Received: 14 February 2025
Revised: 19 June 2025
Accepted: 25 June 2025
First Online: 31 July 2025
Declarations
:
: No author reports any financial interest related to this study.However, Franziska Eckardt received previous speaker fees from Novartis Pharma GmbH. Jakob Siedlecki received previous speaker fees and travel expenses from Novartis Pharma GmbH, Carl Zeiss Meditec AG, Roche AG, Apellis Pharmaceuticals, Allergan GmbH, Abbvie and Heidelberg Engineering GmbH. Jakob Siedlecki received personal consutation fees from Roche AG, Bayer AG, Novartis Pharma GmbH, Allergan GmbH, Abbvie and Apellis Pharmaceuticals. Julian Klaas received previous speaker fees and travel expenses from Norvartis GmbH. Benedikt Schworm received previous speaker fees and travel expenses from Norvatis Pharma GmbH and Topcon Corporation. Johannes Schiefelbein received financial support from Novartis Pharma GmbH. Tina Herold received previous speaker fees from Novartis Pharma GmbH, Bayer Vital GmbH, Abbvie Deutschland GmbH, Roche GmbH. Nikolaus Luft received previous speaker fees Carl Zeiss Meditec AG, Alcon Laboratories Inc., NIDEK Co. Ltd and CenterVue SpA. Siegfried Priglinger received previous speaker fees and travel expenses from Norvartis Pharma GmbH, Oertli AG, Bayer AG, Alcon Pharm GmbH and Allergan GmbH. Anna Lorger Caspar Liesenhoff and Michael Hafner declare no financial disclosures.
: Ethics committee of the Medical Faculty of LMU Munich approval; study number 24-0638. Informed consent for intravitreal injection was obtained from all individual participants included in the study.